Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
GRGRI Bio, Inc. logo

GRI Bio, Inc. (GRI)

NASDAQ · Currency in USD
$1.45 ▲ +0.03 (+2.11%)
At close: Oct 23, 4:00 PM ET. Market closed.
$1.50 ▲ +0.05 (+3.45%)
After hours: Oct 23, 7:30 PM ET

Summary

Previous Close
$1.42
Open
$1.45
Day's Range
$1.45 – $1.53
52 Week Range
$1.36 – $64.12
Volume
64,871
Avg. Volume
262,881
Market Cap
$3.17M
Beta (5Y Monthly)
-0.61
PE Ratio (TTM)
--
EPS (TTM)
-$5.35
Earnings Date
Nov 13, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
Dec 29, 2008
1y Target Est
--

Profile: GRI Bio, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
4
CEO
W. Marc Hertz
Website
gribio.com

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company’s portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses.

Earnings

Next report: Fri, Nov 13, 2026
EPS estimate -$0.84
DateEst.Actual
Aug 14, 2026-$1.19-$0.91Beat
May 13, 2026-$0.91-$1.61Miss
Mar 13, 2026-$29.27-$13.25Beat
Nov 14, 2025-$29.26-$35.85Miss
Aug 14, 2025-$36.69-$36.69Beat
Aug 12, 2025-$1.31-$162.40Miss

Analyst view

Rating: Buy
Buy 100% · Hold 0% · Sell 0%

Get free alerts on GRI and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.